ARCT
Arcturus Therapeutics Holdings Inc
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 1.03B; Volume: 72.37K; AvgVol 3m: 775.57K; Beta: –;
Cost estimate:
P/E: –; EPS: -2.87; EPS growth quarter/prev quarter: -730.00%;
EPS growth this year: 0.50%; EPS growth past 5 years: 33.70%;
EPS ttm: -2.87;
P/S: 101.60; P/B: 9.49; P/Cashflow: ; P/FCF: ;
Sales: 11.26M; Sales growth quarter/prev quarter: -77.50%; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -39.30%; ROE – return on equity: -89.40%; LT Debt/Equity: 0.16; Total Debt/Equity: 0.16;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 22.40%; Insider Transactions:-0.25%;
Institutional Ownership: 52.90%; Institutional Transactions: 185.41%;
Data update: 07/10/2020.